GLP-1 Receptor Agonist Market - By Drug Class (Semaglutide, Dulaglutide, Liraglutide, Exenatide), By Route of Administration (Parenteral), By Application (Type 2 Diabetes, Obesity), By Distribution (Hospital, Retail), Global Forecast, 2023 – 2032

GLP-1 Receptor Agonist Market - By Drug Class (Semaglutide, Dulaglutide, Liraglutide, Exenatide), By Route of Administration (Parenteral), By Application (Type 2 Diabetes, Obesity), By Distribution (Hospital, Retail), Global Forecast, 2023 – 2032

GLP-1 Receptor Agonist Market Size

GLP-1 Receptor Agonist Market size was evaluated to be around USD 22.4 billion in 2022 and is anticipated to exhibit sustainable growth at a CAGR of around 9.6% during the forecast period, i.e., from 2023 to 2032. The growth is attributed primarily to factors such increasing prevalence of chronic diseases such as diabetes and obesity, increasing R&D activities for developing novel therapeutics, advancement in formulation of oral GLP-1 receptor agonist, and increasing awareness about diagnosis and treatment option for diabetes.
 

Glucagon-like peptide-1 (GLP-1) receptor agonists bind and activate the GLP-1 receptor, stimulating glucose-dependent insulin release from the pancreatic islets and slowing gastric emptying. GLP-1 is an important gut-derived hormone that enhances insulin secretion. In the presence of elevated glucose, it increases glucose-dependent insulin synthesis and the in vivo secretion of insulin from pancreatic beta cells. In addition to this, GLP-1 suppresses glucagon secretion, reduces food intake via the reduction of appetite, and promotes beta cell proliferation.
 

GLP-1 receptor agonists are one of the antidiabetics and are suitable initial therapy for patients with type 2 diabetes and those who are at high risk of cardiovascular diseases. In addition to these, it can be used as an initial therapy for high-risk heart failure or chronic kidney disease. GLP-1 receptor agonist therapies facilitate restoring insulin secretory functions, improving glycemic control, and reducing weight in type 2 diabetes patients.
 

COVID-19 Impact

During COVID-19, the global GLP-1 receptor agonist market was obstructed due to the lockdown and travel restrictions imposed by the government all over the globe. Due to this, COVID-19 had a negative impact on the healthcare domain and disrupted the supply chain, from raw materials to manufacturing and delivery. On the other hand, the market was boosted as type 2 diabetes is one of the important risk factors for COVID-19 mortality. GLP-1 receptor agonists were associated with increased ACE2 expression in lungs and heart tissue and showed effectiveness in acute lung injury, along with helpful effects in COVID-19. This has positively impacted the diabetes therapeutics market including GLP-1 receptor agonist, insulin delivery devices, diabetes care devices, digital diabetes management devices and software etc.
 

Later, as COVID instances decreased, the market experienced considerable growth with increasing R&D activities, new product launches, and continuous support and investments from the government.
 

GLP-1 Receptor Agonist Market Trends

The prevalence of chronic diseases like diabetes, cardiovascular diseases, obesity, and many others has been rapidly increasing over the past few decades. The prevalence of diabetes is increasing at an alarming rate all over the globe. For instance, according to the International Diabetes Federation's (IDF) Diabetes Atlas 2021, in 2021, approximately 537 million adults were living with diabetes, and it is estimated that by 2030, the number of diabetic patients will reach 643 million and by 2045, 783 million worldwide. According to the IDF, in 2021, diabetes is expected to cause 6.7 million deaths. Among type 1 and type 2 diabetes, the most common is type 2, which usually occurs in adults.
 

The global obesity crisis is affecting the heart, kidneys, liver, and mental health. It leads to a wide range of diseases like type 2 diabetes, cardiovascular diseases, hypertension, stroke, and cancer. According to the World Health Organization, in 2022, more than 1 billion people were obese, of whom 650 million were adults, 340 million were adolescents, and 39 million were children. The prevalence of diabetes and obesity is still increasing, and the need to treat such chronic diseases has become crucial. Glucagon-like peptide-1 receptor agonists (GLP-1) are a class of drugs mostly used for treating diabetes and obesity. The high prevalence of diabetes and obesity is expected to amplify the growth of the GLP-1 receptor agonist market globally.
 

Due to the rising prevalence and demand for novel therapeutics for treating diseases like diabetes, obesity, cardiovascular disorders and many others are boosting the growth of global market. The pharmaceutical companies are increasing the research and development activities for developing novel GLP-1 receptor agonist drugs in order to overcome the health and mental issues caused by obesity and diabetes.
 

GLP-1 Receptor Agonist Market Analysis

Based on drug class, the global industry is subdivided into semaglutide, dulaglutide, liraglutide, exenatide, and other drug classes. The semaglutide segment dominated the global GLP-1 receptor agonist market in 2022. It is a class of drugs indicated for improving glycemic control in adults with type-2 diabetes mellitus as an adjunct to diet and exercise and used for treating obesity. It is also indicated for adults with type 2 diabetes to reduce the risk of major cardiovascular events. Along with this, the increasing prevalence of diabetes and obesity increases the demand for semaglutide, leading to the growth of this market.
 

Based on route of administration, the GLP-1 receptor agonist market is subdivided into parenteral and oral routes of administration. The parenteral segment held the highest market share in 2022 owing to the advantages offered such as immediate onset of action, better bioavailability, easy absorption of active form of medications and zero chances of interference. Many of the GLP-1 receptor agonist drugs are administered by parenteral routes; for instance, Dulaglutide (Trulicity), Liraglutide (Victoza, Saxenda), Exenatide (Bydureon, Byetta) are available in injections form.
 

Based on application, the global GLP-1 receptor agonist market is classified into type 2 diabetes mellitus, obesity, and other applications. The type 2 diabetes mellitus segment accounted for the largest share in 2022. The GLP-1 receptor agonist plays an important role in stimulating release of insulin and suppressing glucagon secretion when the blood glucose levels are high. They help in treating type 2 diabetes patients and promote weight loss. Factors such as the increasing prevalence of type 2 diabetes, growing demand for treatment, and increased prescriptions of GLP-1 receptor agonist drugs are contributing to the growth of this segment.
 

Based on distribution channel, the global GLP-1 receptor agonist market is subdivided into hospital, retail, and online pharmacies. Among the distribution channel segments, the hospital segment held the highest revenue share of the market in 2022. The large share of this segment can be attributed to the large patient pool towards hospital, wide availability of medicines in hospital pharmacies, and continuous availability of diabetes consultant in the hospitals.
 

Furthermore, the increasing prevalence of chronic diseases, development of new therapies for type 2 diabetes, increasing government initiatives in launching the new drugs, and need for long term treatment of chronic diseases like diabetes and obesity are expected to drive the growth of this segment.
 

Based on region, global GLP-1 receptor agonist market is subdivided into North America, Europe, Asia Pacific, Latin America, and the Middle East, and Africa. In 2022, the North America held the highest revenue in this market, owing to high prevalence of chronic diseases such as diabetes and obesity, increasing investments for R&D for developing new drugs for treating diabetes and obesity, presence of key players, and well-developed healthcare infrastructure in the region. During the forecast period, Asia Pacific segment is anticipated to witness significant growth due to the increasing prevalence of chronic diseases and increased government initiatives and fundings for diagnosis and treatment of diabetes.
 

In North America segment, the U.S. accounted for the highest market share in 2022 due to the better access to treatment options, strong promising pipeline drugs, increasing number of product launches, acquisitions and increasing awareness and demand for GLP-1 receptor agonist products.
 

GLP-1 Receptor Agonist Market Share

The key players in GLP-1 receptor agonist market are

• Eli Lilly and Company
• Sanofi
• Novo-Nordisk A/S
• AstraZeneca
• Pfizer.Inc
• Amgen, Inc.
• Innovent Biologics, Inc.
• PegBio Co., Ltd.
• Sun Pharmaceutical Industries Ltd.
• Boehringer Ingelheim International GmbH

These companies are implementing several strategies such as collaborations, acquisitions, partnerships, mergers, and product launches, etc. to maintain a competitive edge in the industry.
 

GLP-1 Receptor Agonist Industry News

• In March 2023, NHS approved Wegovy, a weight loss injection which mimics the hormone glucagon-like peptide-1 (GLP-1) and suppresses appetite. The NHS will now offer Wegovy, known as semaglutide, to thousands of people living with obesity in England.
   
• In May 2022, US FDA approved Mounjaro (tirzepatide) injection of Eli Lilly and Company for treating type 2 diabetes patients. Mounjaro is once in a week GLP-1 receptor agonist.
   

The GLP-1 receptor agonist market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2018 to 2032 for the following segments

Click here to Buy Section of this Report

By Drug Class

• Semaglutide
• Dulaglutide
• Liraglutide
• Exenatide
• Other drug classes

By Route of Administration

• Parenteral
• Oral

By Application

• Type 2 diabetes mellitus
• Obesity
• Other applications

By Distribution Channel

• Hospital pharmacies
• Retail pharmacies
• Online pharmacies

The above information is provided for the following regions and countries

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Switzerland
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • Rest of Middle East & Africa